Company intelligence / Profile preview

REPROCELL

Ownership: Public · 4978
Development stage: Phase 2

Overview

REPROCELL’s partnered MSC product "Stemchymal" has shown positive Phase II results in Taiwan and Japan for spinocerebellar ataxia. The company’s iPSC-derived GRP program has demonstrated efficacy in preclinical models of ALS and transverse myelitis. Gameto's Fertilo program using REPROCELL’s iPSCs received FDA IND clearance to enter U.S. Phase 3 trials

Therapeutic areas: OtherNeurology
Modalities: Induced pluripotent stem cell derived therapyMesenchymal stem cell therapyCell therapyGene editing (CRISPR-based)Oligonucleotide synthesis
Industry: Biotech

Drug pipeline

1 asset

Stemchymal

Phase 2

Indications: Spinocerebellar ataxia

Partnerships

Steminent Biotherapeutics Inc. (co-development/commercialization of Stemchymal)Q Therapeutics Inc. (collaboration on GRP therapies)Gameto Inc. (iPSC supply/technology partnership)

Beyond the preview

Go deeper on REPROCELL.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REPROCELL.

Explore the full profile